CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Lenalidomide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01782963
NCT01782963Phase 2Completed

A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

Massachusetts General Hospital·interventional·Posted Feb 4, 2013·Updated Oct 31, 2018

In Brief

A Phase 2 clinical trial evaluating Lenalidomide, Bortezomib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 50 participants across 6 sites.

Detailed Summary

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs. The purpose is to learn whether the combination of drugs works in treating a specific cancer. "Investigational" means that the combination of drugs is still being studied. It also means that research doctors are trying to find out more about it. Examples of what they want to learn about are the safest dose to use, the side effects it may cause, and if the combination of drugs works for treating different types of cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2013
Enrollment StartMar 1, 2013
Primary CompletionDec 1, 2016
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.4 years ago

Interventions

Lenalidomidedrug

Bortezomibdrug

Dexamethasonedrug